TY - JOUR
T1 - Addressing gaps in care of people with conditions affecting sex development and maturation
AU - on behalf of COST Actions DSDnet and GnRH Network as well as the European Reference Network for Rare Endocrine Conditions (Endo–ERN)
AU - Hiort, Olaf
AU - Cools, Martine
AU - Springer, Alexander
AU - McElreavey, Ken
AU - Greenfield, Andy
AU - Wudy, Stefan A.
AU - Kulle, Alexandra
AU - Ahmed, S. Faisal
AU - Dessens, Arianne
AU - Balsamo, Antonio
AU - Maghnie, Mohamad
AU - Bonomi, Marco
AU - Dattani, Mehul
AU - Persani, Luca
AU - Audi, Laura
N1 - Publisher Copyright:
© 2019, Springer Nature Limited.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Differences of sex development are conditions with discrepancies between chromosomal, gonadal and phenotypic sex. In congenital hypogonadotropic hypogonadism, a lack of gonadotropin activity results primarily in the absence of pubertal development with prenatal sex development being (almost) unaffected in most patients. To expedite progress in the care of people affected by differences of sex development and congenital hypogonadotropic hypogonadism, the European Union has funded a number of scientific networks. Two Actions of the Cooperation of Science and Technology (COST) programmes — DSDnet (BM1303) and GnRH Network (BM1105) — provided the framework for ground-breaking research and allowed the development of position papers on diagnostic procedures and special laboratory analyses as well as clinical management. Both Actions developed educational programmes to increase expertise and promote interest in this area of science and medicine. In this Perspective article, we discuss the success of the COST Actions DSDnet and GnRH Network and the European Reference Network for Rare Endocrine Conditions (Endo–ERN), and provide recommendations for future research.
AB - Differences of sex development are conditions with discrepancies between chromosomal, gonadal and phenotypic sex. In congenital hypogonadotropic hypogonadism, a lack of gonadotropin activity results primarily in the absence of pubertal development with prenatal sex development being (almost) unaffected in most patients. To expedite progress in the care of people affected by differences of sex development and congenital hypogonadotropic hypogonadism, the European Union has funded a number of scientific networks. Two Actions of the Cooperation of Science and Technology (COST) programmes — DSDnet (BM1303) and GnRH Network (BM1105) — provided the framework for ground-breaking research and allowed the development of position papers on diagnostic procedures and special laboratory analyses as well as clinical management. Both Actions developed educational programmes to increase expertise and promote interest in this area of science and medicine. In this Perspective article, we discuss the success of the COST Actions DSDnet and GnRH Network and the European Reference Network for Rare Endocrine Conditions (Endo–ERN), and provide recommendations for future research.
UR - http://www.scopus.com/inward/record.url?scp=85071276722&partnerID=8YFLogxK
U2 - 10.1038/s41574-019-0238-y
DO - 10.1038/s41574-019-0238-y
M3 - Journal articles
C2 - 31406344
AN - SCOPUS:85071276722
SN - 1759-5029
VL - 15
SP - 615
EP - 622
JO - Nature Reviews Endocrinology
JF - Nature Reviews Endocrinology
IS - 10
ER -